Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 + Pembrolizumab in Advanced Solid Cancers
NCT03254732Phase 1Terminated
- Sponsor
- Polaris Group
- Start
- Jul 2017
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pegargiminase in solid tumor (advanced stage), sponsored by Polaris Group. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 36 months. Started Jul 2017; status: terminated.
02
Drugs
Pegargiminase
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03254732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254732.